Janux Therapeutics, Inc.
JANX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001817713
No open-market purchases or sales by Janux Therapeutics, Inc. insiders were filed in the last 90 days; 197 institutions reported holding it in 13F filings for Q2 2026, worth $933.4M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Janux Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 121
- +57 vs. Q4 2023
- Shares held
- 42.3M
- +8.83M (+26.4%) vs. Q4 2023
- Total value
- $1.59B
- +$1.23B (+343.4%) vs. Q4 2023
- New holders
- 63
- 25 more added
- Sold out
- 6
- 28 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JANX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 197 | $933.4M |
| Q1 2026 | 190 | $827.8M |
| Q4 2025 | 176 | $860.0M |
| Q3 2025 | 174 | $1.59B |
| Q2 2025 | 174 | $1.51B |
| Q1 2025 | 181 | $1.81B |
| Q4 2024 | 216 | $3.43B |
| Q3 2024 | 160 | $2.07B |
| Q2 2024 | 155 | $1.87B |
| Q1 2024 | 121 | $1.59B |
| Q4 2023 | 64 | $359.5M |
| Q3 2023 | 57 | $354.0M |
| Q2 2023 | 54 | $362.1M |
| Q1 2023 | 48 | $369.5M |
| Q4 2022 | 50 | $381.3M |
| Q3 2022 | 49 | $400.3M |
| Q2 2022 | 44 | $353.0M |
| Q1 2022 | 47 | $407.1M |
| Q4 2021 | 46 | $541.6M |
| Q3 2021 | 45 | $571.2M |
| Q2 2021 | 30 | $614.5M |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Janux Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 193,046 | $7.27M | 0.05% | −4,444−2.3% | Reduced |
| Altitude Crest Partners Inc. | 193,300 | $7.28M | 3.12% | +193,300 | New |
| Northern Trust Corp | 201,983 | $7.60M | 0.00% | −2,019−1.0% | Reduced |
| Two Sigma Investments, LP | 224,720 | $8.46M | 0.02% | +180,612+409.5% | Added |
| Samlyn Capital, LLC | 296,391 | $11.2M | 0.19% | +296,391 | New |
| Goldman Sachs Group Inc | 347,171 | $13.1M | 0.00% | +307,223+769.1% | Added |
| Avidity Partners Management LP | 384,245 | $14.5M | 0.51% | +384,245 | New |
| State Street Corp | 399,467 | $15.0M | 0.00% | +51,882+14.9% | Added |
| Geode Capital Management, LLC | 467,547 | $17.6M | 0.00% | +59,357+14.5% | Added |
| Lord, Abbett & Co. LLC | 542,373 | $20.4M | 0.07% | +542,373 | New |
| Cormorant Asset Management, LP | 750,000 | $28.2M | 1.24% | +750,000 | New |
| RTW Investments, LP | 1,000,000 | $37.6M | 0.56% | +1,000,000 | New |
| Vanguard Group Inc | 1,357,960 | $51.1M | 0.00% | +378,477+38.6% | Added |
| BlackRock Inc. | 1,693,991 | $63.8M | 0.00% | −68,110−3.9% | Reduced |
| Janus Henderson Group PLC | 1,965,546 | $74.0M | 0.04% | +34,069+1.8% | Added |
| Citadel Advisors LLC | 2,350,238 | $88.5M | 0.09% | −769,967−24.7% | Reduced |
| Adage Capital Partners GP, L.L.C. | 2,775,672 | $104.5M | 0.20% | +1,420,197+104.8% | Added |
| BVF Inc | 2,919,818 | $109.9M | 3.02% | −1,660,000−36.2% | Reduced |
| OrbiMed Advisors LLC | 4,275,553 | $161.0M | 3.15% | +957,626+28.9% | Added |
| FMR LLC | 7,749,009 | $291.8M | 0.02% | +3,077,796+65.9% | Added |
| Ra Capital Management, L.P. | 9,165,652 | $345.1M | 4.39% | 00.0% | Unchanged |
| Janney Montgomery Scott LLC | 0 | $0 | 0.00% | −51,548−100.0% | Sold out |
| Old Well Partners, LLC | 0 | $0 | 0.00% | −10,300−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −9,345−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −1,734−100.0% | Sold out |
| Raleigh Capital Management Inc. | 0 | $0 | 0.00% | −270−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −134−100.0% | Sold out |